Major Depressive Disorder Clinical Trials in Huntsville, Alabama

7 studies are recruiting for major depressive disorder in Huntsville, Alabama right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

   X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)

   Stage

   Phase 3

   Ages

   18 to 74

   Site

   University of Alabama at Birmingham, Huntsville Regional Medical Campus, Huntsville, Alabama

   Locations

   50 in total

   Run by

   Xenon Pharmaceuticals Inc.

   See if you can join NCT07076407 on ClinicalTrials.gov

2. Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

   This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   University of Alabama at Birmingham, Huntsville, Alabama

   Locations

   69 in total

   Run by

   Intra-Cellular Therapies, Inc.

   See if you can join NCT05850689 on ClinicalTrials.gov

3. NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Huntsville, Alabama

   Locations

   39 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06911112 on ClinicalTrials.gov

4. Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

   The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a l…

   Stage

   Phase 2

   Ages

   18 to 64

   Site

   University of Alabama at Birmingham-Huntsville, Huntsville, Alabama

   Locations

   34 in total

   Run by

   Syndeio Biosciences, Inc

   See if you can join NCT06547489 on ClinicalTrials.gov

5. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Huntsville, Alabama

   Locations

   106 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06966401 on ClinicalTrials.gov

6. Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents

   This study is dedicated to help identify biomarkers for depression and suicide. The purpose of the study is to better understand these links to improve medical and psychiatric care in the future. This research is also to test the effects of standard treatment of depression on improvement in depress…

   Stage

   Not phased

   Ages

   10 to 24

   Site

   UAB Huntsville Regional Medical Campus, Huntsville, Alabama

   Locations

   2 in total

   Run by

   University of Alabama at Birmingham

   See if you can join NCT05437588 on ClinicalTrials.gov

7. MicroRNA Correlates of Childhood Maltreatment and Suicidality

   This is a research study to find out if childhood trauma and stress are associated with depression or suicidal risk. The study will assess the effects of both short-term and long-term stress on biomarker (e.g. miRNA [MiRNA]) levels. miRNAs are a type of RNA (genetic material that is translated into…

   Stage

   Not phased

   Ages

   18 to 60

   Site

   UAB Huntsville Regional Medical Campus, Huntsville, Alabama

   Locations

   2 in total

   Run by

   University of Alabama at Birmingham

   See if you can join NCT04923685 on ClinicalTrials.gov